|
1
|
Coleman RL: Ovarian cancer in 2015:
Insights into strategies for optimizing ovarian cancer care. Nat
Rev Clin Oncol. 13:71–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Metzger-Filho O, Moulin C and D'Hondt V:
First-line systemic treatment of ovarian cancer: A critical review
of available evidence and expectations for future directions. Curr
Opin Oncol. 22:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kipps E, Tan DS and Kaye SB: Meeting the
challenge of ascites in ovarian cancer: New avenues for therapy and
research. Nat Rev Cancer. 13:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roshan Moniri M, Young A, Reinheimer K,
Rayat J, Dai LJ and Warnock GL: Dynamic assessment of cell
viability, proliferation and migration using real time cell
analyzer system (RTCA). Cytotechnology. 67:379–386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pan T, Huang B, Zhang W, Gabos S, Huang DY
and Devendran V: Cytotoxicity assessment based on the AUC50 using
multi-concentration time-dependent cellular response curves. Anal
Chim Acta. 764:44–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kho D, MacDonald C, Johnson R, Unsworth
CP, O'Carroll SJ, du Mez E, Angel CE and Graham ES: Application of
xCELLigence RTCA biosensor technology for revealing the profile and
window of drug responsiveness in real time. Biosensors (Basel).
5:199–222. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bailey CJ: Metformin: Historical overview.
Diabetologia. 60:1566–1576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Romero IL, McCormick A, McEwen KA, Park S,
Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of
type II diabetes and metformin use to ovarian cancer progression,
survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumar S, Meuter A, Thapa P, Langstraat C,
Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake
is associated with better survival in ovarian cancer: A
case-control study. Cancer. 119:555–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bar D, Lavie O, Stein N, Feferkorn I and
Shai A: The effect of metabolic comorbidities and commonly used
drugs on the prognosis of patients with ovarian cancer. Eur J
Obstet Gynecol Reprod Biol. 207:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patel S, Singh N and Kumar L: Evaluation
of effects of metformin in primary ovarian cancer cells. Asian Pac
J Cancer Prev. 16:6973–6979. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mutch DG and Prat J: 2014 FIGO staging for
ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol.
133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Metzgerfilho O, Moulin C and D'hondt V:
First-line systemic treatment of ovarian cancer: A critical review
of available evidence and expectations for future directions. Curr
Opin Oncol. 22:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Howlader N, Noone AM, Krapcho M, Miller D,
Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, et al:
SEER cancer statistics review, 1975–2014. National Cancer
Institute; Bethesda MD: https://seer.cancer.gov/csr/1975_2014/based on
November 2016 SEER data submission, posted to the SEER web site.
April. 2017
|
|
17
|
Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie
HY, Wang X, Zou J, Han X and Feng D: Maintenance chemotherapy for
ovarian cancer. Cochrane Database Syst Rev. 29:CD0074142013.
|
|
18
|
Davidson B and Tropé CG: Ovarian cancer:
Diagnostic, biological and prognostic aspects. Womens Health
(Lond). 10:519–533. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Holmes D: Ovarian cancer: Beyond
resistance. Nature. 527:S2172015. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matulonis UA, Sood AK, Fallowfield L,
Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis
Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kischkel FC, Meyer C, Eich J, Nassir M,
Mentze M, Braicu I, Kopp-Schneider A and Sehouli J: Prediction of
clinical response to drugs in ovarian cancer using the chemotherapy
resistance test (CTR-test). J Ovarian Res. 10:722017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O Donnell RL, Mccormick A, Mukhopadhyay A,
Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, Soohoo S,
Elattar A, et al: The use of ovarian cancer cells from patients
undergoing surgery to generate primary cultures capable of
undergoing functional analysis. PLoS One. 9:e906042014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kar R, Chawla D, Gupta B, Mehndiratta M,
Wadhwa N and Agarwal R: Establishment of primary cell culture from
ascitic fluid and solid tumor obtained from epithelial ovarian
carcinoma patients. Int J Gynecol Cancer. 27:2000–2005. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Robinson DR, Wu YM, Lonigro RJ, Vats P,
Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, et
al: Integrative clinical genomics of metastatic cancer. Nature.
548:297–303. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sherman-Baust CA, Becker KG, Wood Iii WH,
Zhang Y and Morin PJ: Gene expression and pathway analysis of
ovarian cancer cells selected for resistance to cisplatin,
paclitaxel, or doxorubicin. J Ovarian Res. 4:212011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shen D, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sato S and Itamochi H: Ovarian cancer and
drug resistance. Curr Obstet Gynecol Rep. 4:18–25. 2015. View Article : Google Scholar
|
|
30
|
Rattan R, Giri S, Hartmann LC and Shridhar
V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase
dispensable manner. J Cell Mol Med. 15:166–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Do MT, Kim HG, Choi JH and Jeong HG:
Metformin induces microRNA-34a to downregulate the
Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of
wild-type p53 cancer cells to oxidative stress and therapeutic
agents. Free Radic Biol Med. 74:21–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shank JJ, Yang K, Ghannam J, Cabrera L,
Johnston CJ, Reynolds RK and Buckanovich RJ: Metformin targets
ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol.
127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Romero IL, McCormick A, McEwen KA, Park S,
Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of
type II diabetes and metformin use to ovarian cancer progression,
survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gwak H, Kim Y, An H, Dhanasekaran DN and
Song YS: Metformin induces degradation of cyclin D1 via AMPK/GSK3β
axis in ovarian cancer. Mol Carcinog. 56:349–358. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang H, Zhang Z, Wei X and Dai R:
Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and
enhances cisplatin-induced apoptosis in ovarian cancer cells. J
Ovarian Res. 8:32015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li P, Zhao M, Parris AB, Feng X and Yang
X: p53 is required for metformin-induced growth inhibition,
senescence and apoptosis in breast cancer cells. Biochem Biophys
Res Commun. 464:1267–1274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao ZY, Liu Z, Bi MH, Zhang JJ, Han ZQ,
Han X, Wang HY, Sun GP and Liu H: Metformin induces apoptosis via a
mitochondria-mediated pathway in human breast cancer cells in
vitro. Exp Ther Med. 11:1700–1706. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang R, Zhang P, Wang H, Hou D, Li W,
Xiao G and Li C: Inhibitory effects of metformin at low
concentration on epithelial-mesenchymal transition of
CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther.
6:2622015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ling S, Song L, Fan N, Feng T, Liu L, Yang
X, Wang M, Li Y, Tian Y, Zhao F, et al: Combination of metformin
and sorafenib suppresses proliferation and induces autophagy of
hepatocellular carcinoma via targeting the mTOR pathway. Int J
Oncol. 50:297–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chou CC, Lee KH, Lai IL, Wang D, Mo X,
Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal
phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a
signaling axis. Cancer research. 74:1–4795. 2014. View Article : Google Scholar
|
